These findings demonstrate that HDAC inhibition in HCC not only suppresses tumor growth but also promotes metabolic differentiation, offering a compelling therapeutic strategy that targets both the epigenetic landscape and altered metabolism of liver cancer. The gene discussed is HDAC9; the disease is neoplasm.